secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001493152-23-040113
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q3 revenue doubles to $8.9M; net loss widens to $6.3M
-----------------------------------------------------------------

- Total revenues $8.9M, up 106% YoY, driven by Ameluz adoption and price increase.
- Net loss of $6.3M ($4.64 per share) vs net loss of $2.6M ($2.26 per share) in Q3 2022.
- Cash and cash equivalents $3.4M; investment in Biofrontera AG shares valued at $3.3M.
- Raised $4.5M in registered direct offering at-the-market on November 2, 2023.
- Affirms FY2023 revenue growth at least 25% vs 2022; expects cash flow positive within ~1.5 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223040113/0001493152-23-040113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223040113/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer